Would you like to participate ask a question join the surfers in our next episode?

S3-E27.4 – 5th Global NASH Congress Wrap-Up: An Interview with Becky Taub

Rachel Zayas interviews Madrigal Pharmaceuticals Founder, Chief Medical Officer and President of R & D Rebecca Taub on the design and some findings from the MAESTRO clinical trials and the importance of patient advocacy.

On May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of NAFLD topics. In this conversation, Aged Diagnostics CEO Rachel Zayas, who attended the conference for Surfing the NASH Tsunami, interviews Madrigal Pharmaceuticals Founder, Chief Medical Officer and President of R & D Rebecca (Becky) Taub.

Becky’s talk at the Congress focused on some key findings from the MAESTRO Phase 2 cirrhosis arm and Phase 3 non-cirrhosis arm. In addition to sharing data about resmetirom efficacy and safety, she discussed other findings about how resmetirom affects the liver. She discusses one of these findings, the strong impact that resmetirom had on liver volume and the stronger impact that resmetirom had on liver volume relative to liver fat as compared to other modes of action.

From there, the conversation goes on to cover the broad range of non-invasive tests that Madrigal deployed in their trials and some of the thinking behind that decision. As the conversation winds down, Becky discusses her belief in the vital importance of patient advocacy and the upcoming International NASH Day.

Request Transcript of This Episode
Request Transcript
First
Last

NASH & Diabetes Podcast and NASH Tsunami Podcast